vigabatrin has been researched along with Disease Exacerbation in 8 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| "Infantile spasms is a severe infantile seizure disorder that is difficult to treat and has a high morbidity." | 6.71 | The United Kingdom Infantile Spasms Study (UKISS) comparing hormone treatment with vigabatrin on developmental and epilepsy outcomes to age 14 months: a multicentre randomised trial. ( Edwards, SW; Hancock, E; Johnson, AL; Kennedy, CR; Lux, AL; Newton, RW; O'Callaghan, FJ; Osborne, JP; Verity, CM, 2005) |
| "From a group of 201 vigabatrin-exposed individuals with epilepsy, fourteen individuals were identified who were currently taking vigabatrin." | 3.79 | Evolution of visual field loss over ten years in individuals taking vigabatrin. ( Acheson, J; Clayton, LM; Newman, WD; Sander, JW; Sisodiya, SM; Stern, WM, 2013) |
| "Vigabatrin, a structural analogue of gamma-aminobutyric acid (GABA), is used for the treatment of generalized and partial seizures in infants." | 3.73 | Vigabatrin caused rapidly progressive deterioration in two cases with early myoclonic encephalopathy associated with nonketotic hyperglycinemia. ( Coker, M; Gokben, S; Karapinar, B; Polat, M; Serdaroğlu, G; Tekgul, H; Tosun, A; Yurtsever, S, 2006) |
| "Infantile spasms is a severe infantile seizure disorder that is difficult to treat and has a high morbidity." | 2.71 | The United Kingdom Infantile Spasms Study (UKISS) comparing hormone treatment with vigabatrin on developmental and epilepsy outcomes to age 14 months: a multicentre randomised trial. ( Edwards, SW; Hancock, E; Johnson, AL; Kennedy, CR; Lux, AL; Newton, RW; O'Callaghan, FJ; Osborne, JP; Verity, CM, 2005) |
| " In animals dosed during PNDs 7-14 or during PNDs 14-30, the first changes were found in the thalamus." | 1.42 | Vigabatrin-induced CNS changes in juvenile rats: Induction, progression and recovery of myelin-related changes. ( Downes, N; Mullins, P; Rasmussen, AD; Richmond, E; Wegener, KM, 2015) |
| "Vigabatrin has been used as first-line treatment of infantile spasms." | 1.36 | MRI changes associated with vigabatrin treatment mimicking tumor progression. ( Geyer, JR; Ojemann, JG; Pruthi, S; Yang, T, 2010) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 5 (62.50) | 29.6817 |
| 2010's | 3 (37.50) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Clayton, LM | 1 |
| Stern, WM | 1 |
| Newman, WD | 1 |
| Sander, JW | 1 |
| Acheson, J | 1 |
| Sisodiya, SM | 1 |
| Rasmussen, AD | 1 |
| Richmond, E | 1 |
| Wegener, KM | 1 |
| Downes, N | 1 |
| Mullins, P | 1 |
| Riikonen, R | 1 |
| Horton, M | 1 |
| Rafay, M | 1 |
| Del Bigio, MR | 1 |
| Yang, T | 1 |
| Pruthi, S | 1 |
| Geyer, JR | 1 |
| Ojemann, JG | 1 |
| Lux, AL | 1 |
| Edwards, SW | 1 |
| Hancock, E | 1 |
| Johnson, AL | 1 |
| Kennedy, CR | 1 |
| Newton, RW | 1 |
| O'Callaghan, FJ | 1 |
| Verity, CM | 1 |
| Osborne, JP | 1 |
| Tekgul, H | 1 |
| Serdaroğlu, G | 1 |
| Karapinar, B | 1 |
| Polat, M | 1 |
| Yurtsever, S | 1 |
| Tosun, A | 1 |
| Coker, M | 1 |
| Gokben, S | 1 |
| Buoni, S | 1 |
| Zannolli, R | 1 |
| Waterham, H | 1 |
| Wanders, R | 1 |
| Fois, A | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Decreasing Parental Stress and Costs While Improving Overall Satisfaction of Caregivers of Infants With Infantile Spasms on ACTH Therapy Utilizing Innovative Telemedicine Technology: A Randomized Study[NCT04086992] | 40 participants (Anticipated) | Interventional | 2019-10-10 | Recruiting | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 trial available for vigabatrin and Disease Exacerbation
| Article | Year |
|---|---|
The United Kingdom Infantile Spasms Study (UKISS) comparing hormone treatment with vigabatrin on developmental and epilepsy outcomes to age 14 months: a multicentre randomised trial.
Topics: Adaptation, Psychological; Anti-Inflammatory Agents; Anticonvulsants; Child Development; Cosyntropin | 2005 |
7 other studies available for vigabatrin and Disease Exacerbation
| Article | Year |
|---|---|
Evolution of visual field loss over ten years in individuals taking vigabatrin.
Topics: Adult; Anticonvulsants; Disease Progression; Epilepsy; Female; Humans; Longitudinal Studies; Male; M | 2013 |
Vigabatrin-induced CNS changes in juvenile rats: Induction, progression and recovery of myelin-related changes.
Topics: Age Factors; Animals; Animals, Newborn; Brain; Central Nervous System; Disease Progression; Enzyme I | 2015 |
Is the risk of vigabatrin-attributed visual field loss lower in infancy than in later life?
Topics: Adult; Anticonvulsants; Child; Disease Progression; Humans; Infant; Perceptual Disorders; Spasms, In | 2009 |
Pathological evidence of vacuolar myelinopathy in a child following vigabatrin administration.
Topics: Anticonvulsants; Brain; Brain Damage, Chronic; Causality; Cerebral Palsy; Demyelinating Diseases; Di | 2009 |
MRI changes associated with vigabatrin treatment mimicking tumor progression.
Topics: Anticonvulsants; Brain Neoplasms; Disease Progression; Female; Humans; Infant; Oligodendroglioma; Se | 2010 |
Vigabatrin caused rapidly progressive deterioration in two cases with early myoclonic encephalopathy associated with nonketotic hyperglycinemia.
Topics: Anticonvulsants; Disease Progression; Electroencephalography; Epilepsies, Myoclonic; Fatal Outcome; | 2006 |
D-bifunctional protein deficiency associated with drug resistant infantile spasms.
Topics: 17-Hydroxysteroid Dehydrogenases; Anticonvulsants; Disease Progression; DNA Mutational Analysis; Dru | 2007 |